Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact Contact Barchart
Market:

Cybin Inc (CYBN.NE)

Cybin Inc (CYBN.NE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NEO]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NEO]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Cybin (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day Investor Brand Network - Thu Jan 26, 11:32AM CST

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled a virtual R&D Day for Feb. 28, 2023; the event is scheduled...

CYBN.NE : 0.5000 (-1.96%)
CYBN : 0.3990 (-0.25%)
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry FinancialNewsMedia - Thu Jan 26, 7:45AM CST

EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END

CYBN.NE : 0.5000 (-1.96%)
MMED.NE : 4.5700 (+0.66%)
LOBEF : 0.0307 (+2.68%)
LOBE.CN : 0.0400 (unch)
ATAI : 1.8150 (+1.40%)
CMPS : 10.69 (-0.09%)
CYBN : 0.3990 (-0.25%)
MNMD : 3.44 (+1.74%)
Cybin to Host Virtual R&D Day on February 28, 2023 Business Wire - Thu Jan 26, 6:30AM CST

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced that it will host a virtual...

CYBN.NE : 0.5000 (-1.96%)
CYBN : 0.3990 (-0.25%)
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain Business Wire - Wed Jan 18, 6:30AM CST

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced key highlights from the completed...

CYBN.NE : 0.5000 (-1.96%)
CYBN : 0.3990 (-0.25%)
Cybin (NYSE American: CYBN) (NEO: CYBN) Selects Generalized Anxiety Disorder as Target Indication for CYB004 Investor Brand Network - Thu Jan 12, 1:56PM CST

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(R). The company today announced that it has selected Generalized Anxiety Disorder...

CYBN.NE : 0.5000 (-1.96%)
CYBN : 0.3990 (-0.25%)
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004 Business Wire - Thu Jan 12, 6:30AM CST

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biotechnology company focused on progressing Psychedelics to Therapeutics ® today announced that it has selected Generalized...

CYBN.NE : 0.5000 (-1.96%)
CYBN : 0.3990 (-0.25%)
Cybin (NEO: CYBN) (NYSE American: CYBN) Releases Update on Clinical Programs Investor Brand Network - Mon Jan 9, 12:10PM CST

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is discussing upcoming priorities and near-term milestones regarding the status...

CYBN.NE : 0.5000 (-1.96%)
CYBN : 0.3990 (-0.25%)
Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs Business Wire - Sun Jan 8, 4:00PM CST

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today outlined its upcoming priorities and near-term...

CYBN.NE : 0.5000 (-1.96%)
CYBN : 0.3990 (-0.25%)
Cybin (NYSE American: CYBN) (NEO: CYBN) CEO Highlights 2022 as ‘Momentous Year’ Investor Brand Network - Tue Dec 20, 2022

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today issued a year-end summary of its key milestone accomplishments in 2022....

CYBN.NE : 0.5000 (-1.96%)
CYBN : 0.3990 (-0.25%)
Cybin Highlights 2022 Accomplishments and Milestones Business Wire - Tue Dec 20, 2022

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , is pleased to provide a year-end summary of...

CYBN.NE : 0.5000 (-1.96%)
CYBN : 0.3990 (-0.25%)

Barchart Exclusives

Chart of the Day: Chuy's - Try a Little Tex-Mex Barchart - 1 hour ago
The Chart of the Day belongs to the Tex-Mex restaurant chain Chuy's (CHUY). I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart feature... Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot